Hims & Hers Health Inc. Aktie News

While the market fixates on short-term product cycles, Hims & Hers (HIMS) is quietly building a healthcare platform, aiming to control the primary interface for diagnostics, prevention, and personalized treatments. The introduction of "Labs" creates the data layer for continuous health optimization, deepening engagement and enabling increasingly precise, personalized care over time. Scale achie...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, announced that it's heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit “Sick of the System” ad, debuting a new national spot “Rich People Live Longer” with a simple message: the era of health as a luxury good is over, and proact...

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber growth underpin a compelling long-term growth thesis despite recent profit volatility. Significant investments in global expansion, new product lines, and vertical integration are expected to drive ...

Hims & Hers Health Inc  (NYSE:HIMS) shares are up 3.4% to trade at $30.60 at last glance.

Revenue grew nearly 50% year over year in Q3 2025 to ~$600 million, with ARPU rising and free cash flow reaching $79 million. Gross margin declined to ~74% from high-70s levels due to GLP-1 shipping cadence changes, price cuts, and facility expansion inefficiencies. Operating cash flow approached $150 million in the quarter, with over $1 billion in cash and investments supporting reinvestment a...

Amazon could be on the cusp of an artificial intelligence (AI)-driven boom in profitability. Hims & Hers Health stock is pricey, but the company's massive growth potential makes up for it.

Hims & Hers stock has nosedived in the past few months. It has dived by over 56% from its highest point in July last year and is now hovering at its lowest level since April.

Hims & Hers Health remains a speculative buy for aggressive growth investors, driven by its pivot toward precision medicine and AI-enabled healthcare. Recent volatility stems from regulatory risks, the Novo Nordisk partnership breakup, and shifting GLP-1 compounding regulations impacting revenue and investor sentiment. HIMS's valuation sits between telehealth and AI/genomics peers, with substan...